Qure (NasdaqGS:QURE) reports favorable regulatory feedback in the UK and US on its gene therapy AMT-130 for Huntington’s ...

Announced alignment with the U.S. FDA on key elements of the Accelerated Approval pathway for AMT-130 in Huntington’s disease, moving closer to the potential approval of a disease-modifying treatment.

Qure’s fair value estimate has been adjusted from US$37.84 to US$38.48, a small move that still reflects meaningful debate ...

Submission of a UK Marketing Authorization Application for AMT-130 is expected in the third quarter of 2026 ~~ Type B Meeting with U.S. FDA ...

CEO Matthew Kapusta reported, "in the third quarter, we announced positive top line data from our pivotal Phase I/II study of AMT-130 in Huntington's disease, the first gene therapy to demonstrate ...

Publication in Science Translational Medicine shows local striatal delivery of microRNA-gene therapy results in widespread brain huntingtin protein lowering in Huntington’s disease minipigs LEXINGTON, ...

In one of the most incredible single-day moves this year, biotechnology stock uniQure (NASDAQ: QURE) surged by 284% on Sept. 24. This came as the firm released fantastic clinical results for its ...

SAN FRANCISCO, March 16, 2026 /PRNewswire/ -- Investor rights law firm Hagens Berman reminds investors in uniQure N.V. (NASDAQ: QURE) that the Lead Plaintiff Deadline in litigation against the company ...

Management reiterated the expectation for top line pivotal data from AMT-130 and initial Fabry data in September, with a planned BLA submission for AMT-130 in the first quarter of 2026. The team ...

uniQure N.V. (NASDAQ:QURE) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Lake Street Capital reiterated its Buy rating and $30 price target for ClearPoint following uniQure N.V ...

uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA’s Breakthrough ...